Abstract:
:Radiation-induced gliomas represent a relatively rare but an extensively published entity in the neuro-oncologic literature. Extensive retrospective cohort data in pediatric populations after therapeutic intracranial radiation show an increased risk in glioma incidence that is both patient age- and radiation dose/volume-dependent. Data in adults are more limited but show heightened risk in certain groups exposed to radiation. In both populations, there is no statistically increased risk associated with routine exposure to diagnostic radiation. At the molecular level, there are conflicting data concerning whether distinct genetic differences between radiation-induced gliomas and their spontaneously occurring counterparts exist. Clinically, there is understandable reluctance on the part of clinicians to re-treat patients owing to concern for cumulative neurotoxicity. However, available data suggest that aggressive intervention can lead to improved outcomes in patients with radiation-induced gliomas.
journal_name
Expert Rev Neurotherjournal_title
Expert review of neurotherapeuticsauthors
Prasad G,Haas-Kogan DAdoi
10.1002/pmic.200800802subject
Has Abstractpub_date
2009-10-01 00:00:00pages
1511-7issue
10eissn
1473-7175issn
1744-8360journal_volume
9pub_type
杂志文章,评审abstract::Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2021.1848548
更新日期:2021-01-01 00:00:00
abstract::Research into what works in depression is in trouble. All treatments appear equally effective and what happens in research trials does not seem to translate into clinical practice or, to put it another way, clinical practice is not reflected in randomized controlled trials. We run the risk of designing cosmetic trials...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.6.1.41
更新日期:2006-01-01 00:00:00
abstract::Genetic analysis is providing new information on the biological basis of epilepsy at a rapid pace; this article identifies factors acting as major barriers to use of these data for therapy development. Disease heterogeneity is a primary obstacle since so many genes can cause or predispose to epilepsy and the clinical ...
journal_title:Expert review of neurotherapeutics
pub_type: 社论,评审
doi:10.1586/14737175.2016.1115718
更新日期:2016-01-01 00:00:00
abstract::Cognitive behavioral therapy has been found to be efficacious in the treatment of generalized anxiety disorder (GAD). However, reviews of the clinical significance has indicated that approximately 50% of patients with GAD return to a 'well' status following treatment. So how might the field advance? One way is to base...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.161
更新日期:2013-02-01 00:00:00
abstract::In the last two decades clinicians have become increasingly aware of the frequency, importance and functional impact of cognitive dysfunction in multiple sclerosis. There is, however, a dearth of research in this area. In order to further progress in the field of neuropsychological diagnosis it is essential to validat...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.5.731
更新日期:2002-09-01 00:00:00
abstract::Current literature suggests that cigarette smoking is associated with anxiety disorders, but the direction of the association between smoking and anxiety disorders has not been determined. This article provides an overview of the literature in the area of smoking and anxiety disorders in adolescents and current treatm...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.4.533
更新日期:2002-07-01 00:00:00
abstract::Chronic inflammatory demyelinating polyradiculoneuropathy is a neuromuscular disorder for which immunological factors are undoubtedly important in the etiopathogenesis. As clinical recognition of this disorder has improved, immunosuppressive and immunomodulating treatments have emerged as the treatments of choice and ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.3.2.233
更新日期:2003-03-01 00:00:00
abstract::Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.47
更新日期:2012-06-01 00:00:00
abstract::Clomipramine ushered in a new age of pharmacotherapy for obsessive-compulsive disorders, and it also facilitated our understanding of the biological aspects of obsessive-compulsive disorder, focusing on the serotonergic systems. The introduction of selective serotonin reuptake inhibitors has led to great progress in t...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.6.7.945
更新日期:2006-07-01 00:00:00
abstract::The prognosis for patients with malignant glioma, the most common primary intracranial neoplasm, remains dismal despite significant progress in neuro-oncological therapies and technology. This stems from the inability of current treatment strategies to address the highly invasive nature of this disease. Malignant glia...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.3.6.883
更新日期:2003-11-01 00:00:00
abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2017.1378098
更新日期:2017-11-01 00:00:00
abstract::Guillain-Barré syndrome (GBS) includes demyelinating and axonal subtypes with different immunopathologic mechanisms. In acute inflammatory demyelinating polyradiculoneuropathy, segmental demyelination and conduction block are the pathological and electrophysiological correlates of muscle weakness. Slowed conductions a...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.43
更新日期:2009-06-01 00:00:00
abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.3.371
更新日期:2005-05-01 00:00:00
abstract::Bipolar disorder is one of the most serious and prevalent psychiatric disorders. The aim of the present article is to review the efficiency of cognitive-behavioral therapy (CBT) for bipolar patients. Some studies show consistent evidence that cognitive therapy, concomitant to psycho-education and pharmacological treat...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.75
更新日期:2010-07-01 00:00:00
abstract::Understanding of the structure and function of the endocannabinoid system is rapidly evolving. Physiological and pharmacological manipulations based on cannabinoid receptors, ligands and endocannabinoids have explained some medicinal attributes of cannabinoids as used across the world for thousands of years. Plant-der...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.1.1.92
更新日期:2001-09-01 00:00:00
abstract::Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be manag...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.1.105
更新日期:2002-01-01 00:00:00
abstract::Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepressants, and the res...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.42
更新日期:2012-05-01 00:00:00
abstract::Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...
journal_title:Expert review of neurotherapeutics
pub_type: 历史文章,杂志文章,评审
doi:10.1586/14737175.4.6.935
更新日期:2004-11-01 00:00:00
abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2015.988709
更新日期:2015-01-01 00:00:00
abstract::Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder. The development of antipsychotic medications revolutionized treatment for the disorder. However,...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.9.1.73
更新日期:2009-01-01 00:00:00
abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.11.63
更新日期:2011-08-01 00:00:00
abstract::Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.143
更新日期:2010-01-01 00:00:00
abstract::Central pain, which follows brain and spinal cord injury remains an ill-treated entity affecting approximately 1-2 million people worldwide. When oral drugs fail, either immediately or in the long run, the only therapeutic option is neuromodulation, via either electrical or chemical means. The whole spectrum of neurom...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.3.5.591
更新日期:2003-09-01 00:00:00
abstract:INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2018.1476140
更新日期:2018-06-01 00:00:00
abstract::Metabolic dysfunction is one of the early features in Alzheimer's disease (AD) affected brain. Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD. However, the pathogenic role of Abeta remains to be determined. ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.7.11.1517
更新日期:2007-11-01 00:00:00
abstract::Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2021.1847085
更新日期:2021-01-01 00:00:00
abstract::Cognitive dysfunction (CD) affects 40-65% of multiple sclerosis (MS) patients and can have a great functional impact. It can be detected in all the disease phenotypes from the early stages of the disease and tends to progress over time. Memory, complex attention, information processing speed and executive functions ar...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.10.1585
更新日期:2008-10-01 00:00:00
abstract::Central nervous system idiopathic inflammatory demyelinating disorders are a heterogenous group of diseases that share inflammation and demyelination as key features. Although the exact pathophysiology remains to be fully unveiled, these conditions are challenging to clinicians who seek specific therapeutic options fo...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.12.101
更新日期:2012-09-01 00:00:00
abstract::Alzheimer's disease (AD) is the most common cause of dementia and is characterized by an insidious onset and slow deterioration in cognition, activities of daily living (ADL), mood stability and social functioning. The cholinesterase inhibitors (ChEIs), developed based on the cholinergic hypothesis, are currently cons...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.09.23
更新日期:2009-05-01 00:00:00
abstract::Natalizumab is an α-4 integrin antagonist used for the treatment of relapsing multiple sclerosis (MS). Concerns with the drug have a risen owing to a heightened risk of progressive multifocal leukoencephalopathy, which has caused some physicians to interrupt or stop treatment altogether. The article under review evalu...
journal_title:Expert review of neurotherapeutics
pub_type: 评论,杂志文章
doi:10.1586/ern.11.109
更新日期:2011-09-01 00:00:00